Guided Therapeutics (GTHP) Preferred Stock Liabilities (2021)
Guided Therapeutics' (GTHP) quarterly Preferred Stock Liabilities came in at $50000.0 in Q2 2021, down 60.0% quarter-over-quarter from $125000.0 in Q1 2021.
Guided Therapeutics (GTHP) Preferred Stock Liabilities (2021) Analysis & Trends
Guided Therapeutics has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $50000.0 for Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | - |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | - |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Guided Therapeutics | - | - | 458,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 50,000.00 |
| Mar 31, 2021 | 125,000.00 |